News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Why Has 2017 Been A Horrible Year So Far For Biotech Acquisitions?



8/14/2017 9:57:40 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
How many big biotech acquisitions can you name that have occurred so far in 2017?

Johnson & Johnson spent $30 billion to buy Swiss biotech Actelion. That's one. Then there's... well, actually, that's it. J&J's acquisition of Actelion is the only truly big biotech buyout year to date, unless you also want to include Japanese drugmaker Takeda's $5.2 billion deal to buy Ariad in the first quarter.

Read at Motley Fool


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES